Novartis (VTX:NOVN) has been given a CHF 89 target price by Baader Bank in a report issued on Friday. The brokerage presently has a “buy” rating on the stock. Baader Bank’s price target points to a potential upside of 13.55% from the stock’s previous close.

Several other analysts also recently weighed in on NOVN. Barclays set a CHF 70 target price on Novartis and gave the company a “sell” rating in a research note on Monday, June 25th. Deutsche Bank set a CHF 89 target price on Novartis and gave the company a “neutral” rating in a research note on Tuesday, July 3rd. Cfra set a CHF 88 target price on Novartis and gave the company a “buy” rating in a research note on Friday, June 29th. JPMorgan Chase & Co. set a CHF 84 target price on Novartis and gave the company a “neutral” rating in a research note on Tuesday, July 17th. Finally, Berenberg Bank set a CHF 90 target price on Novartis and gave the company a “neutral” rating in a research note on Friday, June 29th. Eleven equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Novartis currently has an average rating of “Hold” and a consensus target price of CHF 88.57.

Shares of VTX:NOVN opened at CHF 78.38 on Friday. Novartis has a twelve month low of CHF 72.45 and a twelve month high of CHF 88.30.

About Novartis

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

Featured Article: Dividend Aristocrat Index

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.